Mars Veterinary Health has new leadership
Mars announced October 16 changes to the leadership of two divisions within its $30 billion-plus Petcare business.
Nefertiti “Nef” Greene, current president of Mars Science & Diagnostics, will move to the role of global president for Mars Veterinary Health in December.
Katie Devine will become the new global president of the Science & Diagnostics division. Both will report to Loïc Moutault, president of Mars Petcare.
Mars Petcare encompasses veterinary care, nutrition, veterinary diagnostics, DNA testing, and wearable health devices. Its Veterinary Health division alone oversees 70,000 veterinary professionals who provide preventive, general, specialty, and emergency veterinary care across 3,000 veterinary clinics worldwide. These include Banfield Pet Hospitals, VCA Animal Hospitals, and BluePearl.
Greene joined Mars in 2022 to lead the newly created Science & Diagnostics division. During the last two years, she has led the growth of the business, building a full diagnostics portfolio, according to the announcement.
Greene has experience in services and healthcare, with an almost 30-year career at companies such as Johnson & Johnson, Bayer, and Forest Laboratories (now Allergan) in roles across both the human pharmaceutical and medical technology sectors.
Devine joined Mars October 21 to lead the Science & Diagnostics division. She comes from Johnson & Johnson where she most recently served as president of its Innovative Medicines’ General Medicines for the U.S., Canada, and & Puerto Rico.
Her career has spanned more than 25 years in consumer health and pharmaceutical businesses across operations, supply chain, marketing, sales, and general management.
Mars, headquartered in McLean, Virginia, is one of the largest privately held companies in the U.S. with net sales totaling more than $50 billion in 2023. Though Mars is the world’s leading confectionery company, the company has said that Mars Petcare accounted for about 60% of the company’s revenue last year.
This past July, Mars acquired the French veterinary diagnostic company Cerba HealthCare’s ownership stake in Cerba Vet and Antagene. Both are now part of the Science & Diagnostics division.
Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland.
Antagene provides expertise in DNA testing for dogs, cats, horses and wildlife. It offers tests globally for diagnosing diseases in pets, as well as supporting scientific initiatives to preserve biodiversity.